Three-month stability of the cogstate brief battery in healthy older adults, mild cognitive impairment, and alzheimer's disease: Results from the Australian imaging, biomarkers, and lifestyle-rate of change substudy (AIBL-ROCS)

Archives of Clinical Neuropsychology

Volumn 28, Issue 4, 2013, Pages 320-330

  Lim, Yen Ying ^a   Jaeger, Judith ^b,c,d   Harrington, Karra ^a   Ashwood, Tim ^e   Ellis, Kathryn A ^a,f   Stöffler, Albrecht ^g   Szoeke, Cassandra ^a,f   Lachovitzki, Rebecca ^h   Martins, Ralph N ^h   Villemagne, Victor L ^a,i   Bush, Ashley ^a   Masters, Colin L ^a   Rowe, Christopher C ^a,i   Ames, David ^a,f   Darby, David ^a   Maruff, Paul ^a,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ASTRAZENECA   (United Kingdom)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d CogState Ltd ^*  (Australia)

^e ASTRAZENECA R AND D   (Sweden)

^f NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^g Stoeffler Consulting   (Germany)

^h EDITH COWAN UNIVERSITY   (Australia)

ⁱ AUSTIN HEALTH   (Australia)

Author keywords

Alzheimer's disease; Assessment; Cognition; Cognitive tests; Neuropsychological tests

Indexed keywords

EID: 84879190102     PISSN: 08876177     EISSN: 18735843     Source Type: Journal    
DOI: 10.1093/arclin/act021     Document Type: Article

References (37)

1. Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimer's and Dementia, 7 (3), 270-279.
2. Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. The New England Journal of Medicine, 367 (9), 795-804.
3. Collie, A., Maruff, P., Darby, D. G., & McStephen, M. (2003). The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. Journal of the International Neuropsychological Society, 9, 419-428.
4. Darby, D., Brodtmann, A., Pietrzak, R. H., Fredrickson, J., Woodward, M., Villemagne, V., et al. (2011). Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. Journal of Alzheimer's Disease, 27 (3), 627-637.
5. Darby, D., Brodtmann, A., Woodward, M., Budge, M., & Maruff, P. (2011). Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease. International Psychogeriatrics, 23 (9), 1376-1385.
6. Duff, K. (2012). Evidence-based indicators of neuropsychological change in the individual patient: Relevant concepts and methods. Archives of Clinical Neuropsychology, 27, 248-261.
7. Ellis, K. A., Bush, A. I., Darby, D., De Fazio, D., Foster, J., Hudson, P., et al. (2009). The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 21 (4), 672-687.
8. Faul, F., Erdfelder, E., Lang, A. G., & Buchner, A. (2007). G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39 (2), 175-191.
9. Faux, N. G., Ritchie, C. W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., et al. (2010). PBT2 rapidly improves cognition in Alzheimer's disease: Additional phase II analyses. Journal of Alzheimer's Disease, 20 (2), 509-516.
10. Francis, P. T., Nordberg, A., & Arnold, S. E. (2005). A preclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease? Trends in Pharmacological Sciences, 26 (2), 104-111.
11. Fredrickson, J., Maruff, P., Woodward, M., Moore, L., Fredrickson, A., Sach, J., et al. (2010). Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies. Neuroepidemiology, 34, 65-75.
12. Hammers, D., Spurgeon, E., Ryan, K., Persad, C., Heidebrink, J., Barbas, N., et al. (2011). Reliability of repeated cognitive assessment of dementia using a brief computerized battery. American Journal of Alzheimer's Disease and Other Dementias, 26 (4), 326-333.
13. Harel, B. T., Darby, D., Pietrzak, R. H., Ellis, K. A., Snyder, P. J., & Maruff, P. (2011). Examining the nature of impairment in visual paired associate learning in amnestic mild cognitive impairment. Neuropsychology, 25 (6), 752-762.
14. Hartley, H. O. (1950). The use of range in analysis of variance. Biometrika, 37, 271-280.
15. Heilbronner, R. L., Sweet, J. J., Attix, D. K., Krull, K. R., Henry, G. K., & Hart, R. P. (2010). Official position of the American Academy of Clinical Neuropsychology on serial neuropsychological assessments: The utility and challenges of repeat test administration in clinical and forensic contexts. The Clinical Neuropsychologist, 24, 1267-1278.
16. Hinton-Bayre, A. D. (2010). Deriving reliable change statistics from test-retest normative data: Comparison of models and mathematical expressions. Archives of Clinical Neuropsychology, 25, 244-256.
17. Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., et al. (2009). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain, 132, 1355-1365.
18. Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. Journal of Consulting and Clinical Psychology, 59 (1), 12-19.
19. Jaeger, J., Hardemark, H. G., & Zettergren, A. (2011). Does repeated daily testing improve measurement sensitivity to the cognitive effects of donepezil in mild to moderate Alzheimer's disease? Paper presented at the Alzheimer's Association International Conference, Paris.
20. Jelic, V., Kivipelto, M., & Winblad, B. (2006). Clinical trials in mild cognitive impairment: Lessons for the future. Journal of Neurology, Neurosurgery, and Psychiatry, 77 (4), 429-438.
21. Kantarci, K., Lowe, V., Przybelski, S. A., Weigand, S. D., Senjem, M. L., Ivnik, R. J., et al. (2012). APOE modifies the association between Ab load and cognition in cognitively normal older adults. Neurology, 78 (4), 232-240.
22. Lim, Y. Y., Ellis, K. A., Harrington, K., Ames, D., Martins, R. N., Masters, C. L., et al. (2012). Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. Journal of Clinical and Experimental Neuropsychology, 34 (4), 345-358.
23. Lim, Y. Y., Ellis, K. A., Pietrzak, R. H., Ames, D., Darby, D., Harrington, K., et al. (2012). Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology, 79, 1645-1652.
24. Lim, Y. Y., Pietrzak, R. H., Snyder, P. J., Darby, D., & Maruff, P. (2012). Preliminary data on the effect of culture on the assessment of Alzheimer's disease related verbal memory impairment with the International Shopping List Test (ISLT). Archives of Clinical Neuropsychology, 27 (2), 136-147.
25. Lim, Y. Y., Prang, K. H., Cysique, L., Pietrzak, R. H., Snyder, P. J., & Maruff, P. (2009). A method for cross-cultural adaptation of a verbal memory assessment. Behavior Research Methods, 41 (4), 1190-1200.
26. Maruff, P., Collie, A., Darby, D., Weaver-Cargin, J., Masters, C., & Currie, J. (2004). Subtle memory decline over 12 months in mild cognitive impairment. Dementia and Geriatric Cognitive Disorders, 18, 342-348.
27. Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., et al. (2010). Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology, 74, 201-209.
28. Pietrzak, R. H., Maruff, P., & Snyder, P. J. (2009). Methodological improvements in quantifying cognitive change in clinical trials: An example with single-dose administration of Donepezil. Journal of Nutrition, Health and Aging, 13 (3), 268-273.
29. Roberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Pankratz, V. S., Boeve, B. F., et al. (2008). The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology, 30 (1), 58-69.
30. Rogers, S. L., Doody, R. S., Mohs, R. C., & Friedhoff, L. T., & the Donepezil Study Group. (1998). Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Archives of Internal Medicine, 158 (9), 1021-1031.
31. Rowe, C. C., Ackermann, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., et al. (2008). Imaging of amyloid b in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. The Lancet Neurology, 7 (2), 129-135.
32. Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., et al. (2010). Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 31, 1275-1283.
33. Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., et al. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 73 (24), 2061-2070.
34. Small, G. W., Siddarth, P., Kepe, V., Ercoli, L. M., Burggren, A. C., Bookheimer, S. Y., et al. (2012). Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Archives of Neurology, 69 (2), 215-222.
35. Snyder, P., Bednar, M. M., Cromer, J. R., & Maruff, P. (2005). Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinester-ase inhibitor. Alzheimer's and Dementia, 1 (2), 126-135.
36. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's and Dementia, 7 (3), 280-292
37. Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., et al. (2011). Longitudinal assessment of Ab and cognition in aging and Alzheimer disease. Annals of Neurology, 69 (1), 181-192.